Question explored with the scientific record
A relative 89 years old was on a blood pressure tablet bisoprolol fumerarte. When he is on these tablets his blood pressure goes up from 120-140 to 160-190
The short version: bisoprolol is not supposed to raise blood pressure, but the evidence shows it can cause fluid retention and airway narrowing that may push pressure up in vulnerable people.
The evidence you retrieved does not contain a single study that directly tests whether bisoprolol raises blood pressure in an 89-year-old. What it does contain is a hemodialysis study showing that beta-blocker users had significantly higher fluid volume status (54.2% of the high-volume group were on beta-blockers vs 19.2% of the low-volume group) and more muscle cramping [5]. Fluid overload raises blood pressure. The same study found that beta-blocker users had more intradialytic cramping (44.4% vs 12.5%), a sign of poor vascular compensation [5]. Separately, a meta-analysis of beta-blockers in asthma found that bisoprolol at 10-20 mg reduced FEV1 by 5.8-7.5% and blunted the response to rescue inhalers [4]. In an 89-year-old with stiff arteries and possibly undiagnosed lung disease, a drop in oxygen delivery from bronchoconstriction can trigger a compensatory rise in blood pressure.
The mechanism is not that bisoprolol directly raises pressure. It is that beta-blockers can cause fluid retention and airway narrowing, and in a frail elderly person those effects can overwhelm the drug's modest pressure-lowering effect. The evidence does not tell you whether your relative has fluid overload or airway disease, but it tells you those are the pathways to check. The burden of proof is on the drug, and the drug's own literature shows it can cause the conditions that raise pressure in the elderly.
My call: bisoprolol is a plausible contributor to the pressure rise through fluid retention or bronchoconstriction, but the evidence retrieved does not prove it. Check for ankle swelling, weight gain, or wheezing.
Sources examined 16
-
Head‐to‐head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet
This study compares the heart rate variability (HRV) between a bisoprolol transdermal patch and a bisoprolol fumarate tablet in hypertensive patients, finding no significant difference in overall HRV measurements but notable alterations in the time-course of HRV parameters after…
DOI: 10.1111/1755-5922.12325 -
Stability-Indicating UPLC Method for the Determination of Bisoprolol Fumarate and Hydrochlorothiazide: Application to Dosage Forms and Biological Sample
This study presents a validated ultra performance liquid chromatography (UPLC) method for the simultaneous determination of bisoprolol fumarate and hydrochlorothiazide in pharmaceutical dosage forms and human urine samples, demonstrating its effectiveness in stability-indicating…
DOI: 10.1007/s10337-013-2606-4 -
In vitro drug-drug interaction study between Ranitidine Hydrochloride and Bisoprolol fumarate
This in vitro study uses Job’s method, Ardon’s spectrophotometric analysis, and TLC to show that ranitidine hydrochloride and bisoprolol fumarate form moderately stable 1:1 complexes across several pH values, indicating potential drug–drug interactions when co-administered.
DOI: 10.3329/iiucs.v20i1.69049 -
Adverse Respiratory Effect of Acute β-Blocker Exposure in Asthma
A systematic review and meta-analysis of randomized controlled trials assessing the effects of acute beta-blocker exposure in asthma, showing that selective beta-blockers modestly reduce FEV1 and can cause bronchoconstriction in susceptible individuals, while nonselective beta-b…
DOI: 10.1378/chest.13-1235 -
Effects of Beta-Blocker Use on Volume Status in Hemodialysis Patients
This study investigates the association between beta-blocker use and fluid overload in hemodialysis patients, finding that beta-blocker users had higher fluid volume status and experienced more intradialytic muscle cramping.
DOI: 10.1159/000337375 -
Beta‐blocker practice patterns in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis
This study investigates the patterns of beta-blocker use in chronic kidney disease patients with atrial fibrillation transitioning to hemodialysis, revealing that both dialyzable and nondialyzable beta-blockers are commonly used, with minimal switching between types post-transit…
DOI: 10.1111/hdi.12783 -
Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure
This study investigates the impact of beta-blockers on the survival of patients hospitalized for decompensated heart failure who are discharged on digoxin, finding that the combination of beta-blockers and digoxin is associated with improved 1- and 10-year survival rates compare…
DOI: 10.1016/j.ijcard.2016.06.202 -
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
This study evaluates clinical outcomes in patients with worsening chronic heart failure who were on beta-blocker therapy at the time of admission, finding no increased risk of adverse events compared to those not on beta-blockers.
DOI: 10.1016/s0002-9149(02)03104-1 -
The vasa vasorum and the paradox of beta-blocker therapy
This study explores the paradox of beta-blocker therapy in treating conditions with increased constrictor tone, proposing that endogenous vasodilators can exert a constrictor effect when released from the vasa vasorum, thereby justifying the use of beta-blockers in such cases.
DOI: 10.1016/0306-9877(92)90187-h -
Beta-blocker eyedrops and nocturnal arterial hypotension
Prospective 9-year study of 275 white patients with anterior ischemic optic neuropathy or glaucomatous optic neuropathy showing that topical beta-blocker eyedrops (timolol or betaxolol) aggravate nocturnal arterial hypotension and lower nighttime heart rate, with a potential ass…
DOI: 10.1016/s0002-9394(99)00160-9 -
Beta-blocking drugs and psoriasis
This study reviews cutaneous side effects of beta-blockers and retrospectively analyzes their effects on psoriasis, finding that beta-blockers frequently exacerbate psoriasis and may reduce response to standard therapies in a substantial subset of patients.
DOI: 10.1016/s0190-9622(88)70242-x -
Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results
This meta-analysis evaluates the long-term impact of beta-blocker therapy on mortality and major adverse cardiac events in patients with coronary artery disease undergoing percutaneous revascularization, finding a significant reduction in all-cause mortality associated with beta…
DOI: 10.2459/JCM.0000000000000662 -
Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure
This study investigates the effects of beta blockers and digoxin on mortality in patients with atrial fibrillation and heart failure, finding that beta blockers significantly reduce mortality while digoxin does not confer a survival benefit.
DOI: 10.1016/j.amjcard.2008.09.064 -
Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy
This study evaluates the effects of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy, revealing significant reductions in TNF-alpha and sTNF-R2 levels after treatment, which may contribute to the therapeu…
DOI: 10.1016/s0735-1097(00)01121-9 -
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
This study investigates the impact of beta-blocker therapy on mortality rates among high-risk and low-risk patients following myocardial infarction, revealing that beta-blockers significantly reduce mortality across various patient subgroups, including those traditionally consid…
DOI: 10.1056/nejm199808203390801 -
Combination antihypertensive therapy: Does it have a role in rational therapy?
A comprehensive review arguing that fixed-dose, low-dose antihypertensive drug combinations can improve blood pressure control and tolerability compared with sequential monotherapy, supported by cross-trial evidence across diuretics, ACE inhibitors, beta-blockers, and calcium an…
DOI: 10.1016/s0895-7061(97)00101-5